DEVELOPMENT OF FORMULARY SYSTEM IN UKRAINE
Author(s)
Vashchenko O1, Zaliska O1, Piniazhko O2
1Danylo Halytsky Lviv National Medical University, Lviv, Ukraine, 2National EML Committee, Lviv, Ukraine
Presentation Documents
OBJECTIVES: In 2009 the Ministry of Health of Ukraine (MoH) issued the Order No.529 “About the development of formulary system of pharmaceutical supply of healthcare organizations” and introduced the conceptual principles for the development of State Formulary of Ukraine (SFU). The aim of this work was to analyze the development of SFU. METHODS: analysis of legislative documents. RESULTS: Development of SFU and ensuring its implementation was entrusted to Central Formulary Committee. SFU, 1st edition was launched in 2009 and from this time SFU is reviewed every year. Currently 10 editions of SFU have been published, and project of SFU 11th is going to be submitted. According to the MoH Order No.429, 2014, drugs to be included into SFU must be registered in the State Register of Ukraine; have use experience for not less than 2 years; demonstrate high quality, effectiveness, and safety; be cost-effective. SFU includes chapters structured in accordance with medicines, which are used for pharmacotherapy of the diseases and conditions regarding to the direction of medicine, where the conservative treatment prevail. The first edition of SFU consists of 19 chapters, new chapters were added to SFU 3rd (”Vitamins and minerals”) and SFU 5th (“Vaccines and anatoxins”); the latest SFU 10th contains 21 chapters. To improve further development of formulary system in Ukraine, a new composition of Central Formulary Committee was submitted in 2018. CONCLUSIONS: Formulary system in Ukraine is constantly developing. There is a need for further legislative implementation of SFU with an appropriate funding from state and local budget.
Conference/Value in Health Info
2019-05, ISPOR 2019, New Orleans, LA, USA
Value in Health, Volume 22, Issue S1 (2019 May)
Code
PNS76
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Formulary Development
Disease
No Specific Disease